Search results for: 'capture made'

12 Aug 2021  |  North America  |  Frost Radar

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

The change in reimbursement for diagnostic testing, pressure from PAMA, regulatory trends in Europe, demand for large-scale testing, shift to precision diagnostics, emerging companies, and evolving business models demand assessing portfolio, evaluating competitor strategies, and exploring opportunities for business growth. The competitive nature of...

23 Feb 2021  |  North America  |  Market Research

AI-Based Image Analysis Tools and Cloud-Based Deployment to Expand the Global Digital Pathology Market

Increased Demand for Remote Pathology Services and Centralization of Digital Pathology Workflow in Hospital Networks to Spark New Growth Opportunities

Infographics

×

The Transformational Health team at Frost & Sullivan provides critical insights into the global digital pathology market, highlighting key growth opportunities, market revenue forecast, and business models that will play an essential role in its growth. The study segments the market by product (hardware, software, and storage solutions) and region ...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

20 Jan 2025  |  Global  |  Market Research

Global Cardiac Biomarkers Diagnostics Industry, 2024-2029

Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth in Cardiac Biomarkers Diagnostics

Infographics

×

The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highligh...

27 Jan 2020  |  Global  |  Market Research

Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

Infographics

×

Key Issues Addressed

The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

23 Aug 2018  |  Europe  |  Market Research

Western European Clinical Laboratory Services Market, Forecast to 2022

Clinical Labs to Transform into Health Information Companies and Increasingly Participate in Clinical Decision Support

Infographics

×

Key Issues Addressed

Diagnostics has inarguably become an integral part of healthcare system, moving from reactionary science to predictive science; playing a vital role throughout the care continuum. While rising burden of chronic diseases, drug-resistant diseases and the increasing proportion of elderly population are the organic growth drivers, the shift towards cre...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...